Educational research & price index · Independent Janoshik & MZ Biolabs COA verification

← Verified COAs & $/mg for this compound

Guide|50 CitationsRecovery & HealingFemale-friendly

BPC-157 Research Dosing Reference

Also known as: Body Protection Compound-157, Pentadecapeptide, PL 14736

Dose Range
200–500 mcgResearch range
0Typical research window: 200–500 mcg600 mcg

Studied in tissue-repair & gastrointestinal research — not a recommendation. Most SubQ protocols evaluate 250 mcg once or twice daily (200–500 mcg/day total).

Protocol at a Glance
How Often
1–2× daily

Once daily (250–500 mcg) or split AM/PM (250 mcg twice daily)

A Typical Run
4–12 weeks

Typically run for 4–8 weeks until soft-tissue recovery plateaus, followed by 2–4 weeks off.

How It's Taken
Vial

SubQ injection · IM injection · Oral (arginate salt for gut)

Evidence
Emerging

Extensive animal & mechanistic studies + early human clinical data

Half-Life & 72-Hour Clearance Shape
Not established in humans

Not established in humans; rat pharmacokinetic studies report a short plasma half-life (under 1 hour)

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 200 mcg8 units
High end: 500 mcg20 units

All U-100: 100 units = 1 mL. 25 doses in the vial at the low end (10 doses at the high end).

Track the doses you run

Save BPC-157 to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

BPC-157 supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Ascension Peptides50% OFF AUTO-APPLIED
Batch COAs (Kovera Labs, MZ Biolabs) on product page
US Domestic Vial
50% Off First Order Link
$24.50 net$49.00
10mg Lyophilized Vial
$2.45/mg$4.90/mg retail
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$200.00
50mg vial
$4.00/mg
Ameano Peptides
Batch COA portal on store site
US Domestic Vial
List price (verified Oct 30)
$44.00
10mg vial
$4.40/mg
Protide Health
Per-lot COA (Freedom Diagnostics, HPLC-MS) on product page
US Domestic Vial
List price
$195.00
40mg vial
$4.88/mg
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$51.00
10mg vial
$5.10/mg
Peptyes
Horizon Analytical UPLC-MS COA, lot DPS-9628420 (99.42%); COA names Privilege Bio Labs (Peptyes says: its manufacturer)
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDEPROTOCOLS takes 10% off at checkout
$54.00
10mg vial
$5.40/mg
SwissChems
Independent test results linked on store
US Domestic Vial
Verified Partner Link
$59.95
10mg Lyophilized Vial
$6.00/mg
Polaris Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$60.00
10mg vial
$6.00/mg
Healius Peptides
Third-party HPLC COA on product page, lot HP9520821385-10 (99.89% HPLC)
US Domestic Vial
Current USD price (store sale vs regular $79.95; no partner coupon; verified Nov 10, 2026)
$69.95$79.95
10mg lyophilized vial (42 in stock)
$7.00/mg$8.00/mg retail
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$153.99
20mg vial
$7.70/mg
Direct Peptides
COA per store product page
US Domestic Vial
List price (last verified Nov 4, 2026; store now requires sign-in)
$39.00
5mg vial
$7.80/mg
Biotech Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$92.00
10mg vial
$9.20/mg
Core Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$97.00
10mg vial
$9.70/mg
Limitless Peptides
COA per store product page
US Domestic Vial
Code: PEPTIDEPROTOCOLS
$99.00
10mg vial
$9.90/mg
BioLongevity Labs
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$99.97
10mg vial
$10.00/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

2026 FDA 503A Cat-2 UpdateTier 3 — Translational Animal & Clinical Obs
Pharmacological Class
Synthetic 15-AA Gastric Cytoprotective & Angiogenic Pentadecapeptide
Administration Route
Under-the-skin injection (SubQ systemic/peritendinous) or Stable Arginate Oral Capsule (GI-local)
2026 FDA & 503A Status
Not FDA-approved. In April 2026, the FDA removed 14 peptides (including BPC-157, Thymosin Beta-4/TB-500, CJC-1295, Ipamorelin, AOD-9604, Semax, Selank, and DSIP) from the Category 2 503A Interim Bulks List pending formal July 2026 PCAC rulemaking. Available as COA-verified research reference standards or via specialized physician telehealth guidance.
WADA Sport Status
Strictly Prohibited at All Times — WADA Section S2.2 (Peptide Hormones, Growth Factors, GH Fragments, BPC-157 & Thymosin-β4)
Evidence Tier
Tier 3 — Translational Animal & Clinical Obs: Replicated mammalian preclinical models plus extensive off-label physician & community protocol tracking
What is a Peptide?

A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.

Bottom Line Up Front

BPC-157 is a synthetic pentadecapeptide derived from gastric juice. Strong animal data for tendon, muscle, and gut healing. Limited human clinical trials. Often called the "Wolverine peptide" in biohacking circles, but human evidence is preliminary.

Best evidence for

Tendon repair, muscle healing, gut ulcer healing (animal data)

Weakest evidence for

Cognitive enhancement, systemic anti-aging

Pharma equivalent

None

Studies on file

50 (26 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. BPC-157 is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Research has investigated its potential effects on tissue healing, angiogenesis, and cellular repair mechanisms.

Mechanisms of Action

  • Upregulates growth hormone receptor expression
  • Promotes angiogenesis via VEGF pathway
  • Modulates nitric oxide synthesis
  • Influences collagen formation and organization

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Tendon Healing Study
published study
10 μg/kgDaily14 daysSubcutaneousanimal
Gastric Ulcer Protocol
published study
10 μg/kgDaily7 daysOralanimal
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (BPC-157)

Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

hs-CRP (High-Sensitivity C-Reactive Protein)

Day 0 + Wk 6–8

Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.

Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.

ESR (Sedimentation Rate) & Ferritin

Day 0 + Wk 6–8

Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.

Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.

CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)

Day 0 + Wk 6–8

Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).

Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).

CMP (Liver/Kidney) + Serum Copper & Zinc Ratio

Day 0 + Wk 6–8

Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.

Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

26 Human24 Animal

Although preclinical studies are promising, there is a current lack of clinical trials. This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.

Limitations: No placebo control reported. Review article — no new primary data.

2026|Journal of the American Academy of Orthopaedic Surgeons. Global research &amp; reviews
PubMed

BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability.

Limitations: No placebo control reported. Review article — no new primary data.

2026|The American journal of sports medicine
PubMed

This generated the attention of experts, as BPC 157 has been offered for sale on many websites. We also present recent interest in BPC 157 as reflected in a number of patent applications and granted patents.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2025|Pharmaceuticals (Basel, Switzerland)
PubMed

This systematic review of level IV and level V studies suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries. Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.

Limitations: No placebo control reported. Review article — no new primary data.

2025|HSS journal : the musculoskeletal journal of Hospital for Special Surgery
PubMed

BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and has demonstrated regenerative properties across numerous animal models. It activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2025|Current reviews in musculoskeletal medicine
PubMed

However, this has not slowed the recent exponential growth of the multi-billion-dollar industry in the development of therapeutic peptides. As orthopaedic surgeons and team physicians, we should stay up to date with the latest pharmacokinetic, safety, ethical, and legal profiles and regulations regarding synthetic peptide supplementation for injury recovery and sports performance optimization in our patients, from elite athletes to fitness fanatics, because they will continue to seek the latest and greatest in treatment options and will be approaching us with questions on their results, risks, and benefits.

Limitations: No placebo control reported. Review article — no new primary data.

2025|Arthroscopy : the journal of arthroscopic &amp; related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association
PubMed

The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels.&#xa0;The BPC-157 peptide infusion was tolerated, with no side effects reported.

Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported.

2025|Alternative therapies in health and medicine
PubMed

decrease), always combined with the counteraction of free radical formation, and, in mice and rats, BPC 157 therapy counteracts Parkinson's disease-like and Alzheimer's disease-like disturbances. Thus, BPC 157 therapy means targeting angiogenesis and NO's cytotoxic and damaging actions but maintaining, promoting, or recovering their essential protective functions.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2025|Pharmaceuticals (Basel, Switzerland)
PubMed

Immediately post-injury, and at 1, 2, 3, 5, 7, 14, 21, 28, 60, and 90 days post-injury, quadriceps muscle-to-bone detachment showed definitive healing failure (impaired walking and permanent knee flexure). Contrarily, macro/microscopic, ultrasonic, magnetic resonance, biomechanical, and functional assessments revealed that BPC 157 therapy recovering effects for all time points were consistent.

Limitations: Animal study only — human translation uncertain.

2025|Pharmaceutics
PubMed

This serves to counteract multiorgan and vessel failure, including lesions and hemorrhages in the brain, heart, lung, liver, kidney and gastrointestinal tract, thrombosis, peripherally and centrally, intracranial (superior sagittal sinus), portal and caval hypertension and aortal hypotension, occlusion/occlusion-like syndrome, advanced Virchow triad circumstances, and free radical formation acting as a membrane stabilizer and free radical scavenger. Likewise, not only in ACS/IAH resolving, but also in other occlusion/occlusion-like syndromes, this "bypassing key" could be an effect of the essential endothelial cytoprotective capacity of BPC 157 and a particular modulatory effect on the NO-system, and a rescuing impact on vasomotor tone.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2025|Pharmaceuticals (Basel, Switzerland)
PubMed

Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

Limitations: Animal study only — human translation uncertain.

2025|Current neuropharmacology
PubMed

This article discusses the lengthy review by Pedrag Sikiric and twenty one (21) co-authors in Inflammopharmacology (2024) 32:3119-3161.

Limitations: No placebo control reported.

2025|Inflammopharmacology
PubMed

Furthermore, close BPC 157/NO-system relations with the gasotransmitters crossing the cell membrane and acting directly on molecules inside the cell may envisage particular interactions with receptors on the plasma membrane of their target cells. Finally, there is nerve-muscle relation in various muscle disturbance counteractions, and nerve-nerve relation in various encephalopathies counteraction, which is also exemplified specifically by the BPC 157 therapy application.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2024|Pharmaceuticals (Basel, Switzerland)
PubMed

Moreover, the healing of fistulas, both external and internal, colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, colovesical, and rectovaginal in rats, perceived as anastomoses made between two different tissues which are normally not connected, may also be indicative. This may be a particular reconnection of the parts of the gastrointestinal tract to re-establish adequate integrity depending on the tissue involved, given that both various intestinal anastomoses and various fistulas (intestinal and skin were accordingly healed simultaneously as the fistulas disappeared) were all healed.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2024|Pharmaceuticals (Basel, Switzerland)
PubMed

Complete resolution of symptoms after one treatment was reported in 10 of 12 patients, who rated their success at 100%. The remaining 2 of 12 patients rated their success at 80%, with most symptoms resolved but about 20% of their symptoms lingering.

Limitations: No placebo control reported.

2024|Alternative therapies in health and medicine
PubMed

Contrary, all BPC 157-treated rats have closed both defects, duodenal and colonic, no fistula leakage (finally, maximal instilled volume corresponds to healthy rats), no cachexia, the same weight as before surgery, no diarrhea, markedly less adhesion formation and intestinal passage obstruction. Thus, BPC 157 regimens resolve the duodenal/colon lesions and duodenocolic fistulas in rats, and rapid vessels recovery appears as the essential point in the implementation of the cytoprotection concept in the fistula therapy.

Limitations: Animal study only — human translation uncertain.

2024|Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
PubMed

Furthermore, given in other eye disturbances (i.e., retinal ischemia), BPC 157 instantly breaks a noxious chain of events, both at an early stage and an already advanced stage. Thus, we further advocate BPC 157 as a therapeutic agent in ocular disease.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2023|Pharmaceuticals (Basel, Switzerland)
PubMed

In particular, progressing thrombosis, both peripherally and centrally, and heart arrhythmias and infarction that would consistently occur were fully counteracted and/or almost annihilated. To conclude, we suggest further BPC 157 therapy applications.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2023|Pharmaceuticals (Basel, Switzerland)
PubMed

Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways. (Current medicinal chemistry, 2023)

Limitations: No placebo control reported.

2023|Current medicinal chemistry
PubMed

As recovery with BPC 157 therapy commonly and rapidly occurred, reversing the collapsed azygos vein to the rescuing collateral pathway might initiate rapid direct blood delivery and start blood flow reorganization. In conclusion, we suggest BPC 157 therapy to resolve further vascular and embolization injuries.

Limitations: Animal study only — human translation uncertain.

2023|Pharmaceuticals (Basel, Switzerland)
PubMed

Further, the BPC 157 therapy might be the recovery for the disabled heart functioning, and disabled smooth muscle functioning (various sphincters function recovery). Finally, BPC 157, native and stable in human gastric juice, might be a prototype of anti-ulcer cytoprotective peptide for the muscle therapy with high curing potential (very safe profile (lethal dose not achieved), with suited wide effective range (&#xb5;g-ng regimens) and ways of application).

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2022|Biomedicines
PubMed

This might be the upgrading of the minor vessel to take over the function of the disabled major vessel, competing with and counteracting the Virchow triad circumstances devastatingly present, making possible the recruitment of collateral blood vessels, compensating vessel occlusion and reestablishing the blood flow or bypassing the occluded or ruptured vessel. As a part of the counteraction of the severe vessel and multiorgan failure syndrome, counteracted were the brain, lung, liver, kidney, gastrointestinal lesions, and in particular, the counteraction of the heart arrhythmias and infarction.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2022|Biomedicines
PubMed

Meantime, several reviews suggest that BPC 157, which does not have a lethal dose, has profound cytoprotective activity, used to be demonstrated in ulcerative colitis and multiple sclerosis trials. Likely, it may bring the theory to practical application, starting with the initial argument, no degradation in human gastric juice for more than 24 h, and thereby, the therapeutic effectiveness (including via a therapeutic per-oral regimen) and pleiotropic beneficial effects.

Limitations: No placebo control reported.

2022|World journal of gastroenterology
PubMed

BPC 157 reduced levels of all necrosis markers, CK, CK-MB, LDH, and cTnT, and attenuated gross (no visible infarcted area) and histological damage, ECG (no ST-T ischemic changes), and echocardiography (preservation of systolic left ventricular function) damage induced by isoprenaline. Its effect was associated with a significant decrease in oxidative stress parameters and likely maintained NO system function, providing that BPC 157 interacted with eNOS and COX2 gene expression in a particular way and counteracted the noxious effect of the NOS-blocker, L-NAME.

Limitations: Animal study only — human translation uncertain.

2022|Biomedicines
PubMed

As leading symptoms, increased intraocular pressure and mydriasis, as well as degeneration of retinal ganglion cells, optic nerve head excavation and reduction in optic nerve thickness, generalized severe irregularity of retinal vessels, faint presentation of choroidal vessels and severe optic nerve disc atrophy were all counteracted. In conclusion, we claim that the reversal of the episcleral veins cauterization glaucoma appeared as a consequence of the BPC 157 therapy of the vessel occlusion-induced perilous syndrome.

Limitations: Animal study only — human translation uncertain.

2022|Biomedicines
PubMed

Future Directions: BPC 157 rapidly increases various genes expression in rat excision skin wound. This would define the healing in the other tissues, that is, gastrointestinal tract, tendon, ligament, muscle, bone, nerve, spinal cord, cornea (maintained transparency), and blood vessels, seen with BPC 157 therapy.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2021|Frontiers in pharmacology
PubMed

Of the 16 patients, 12 had received only BPC 157 as an intra-articular injection. In this group, 11 of the 12 patients (91.6%) had significant improvement in knee pain, whereas 1 patient (8.3 %) had no improvement.

Limitations: No placebo control reported.

2021|Alternative therapies in health and medicine
PubMed

Likewise, in BPC 157 therapy, there is specific support for each of these topics: counteracted encephalopathies; alleviated vascular occlusion disturbances (stroke); counteracted dopamine disturbances (dopamine receptors blockade, receptors super sensitivity development, or receptor activation, over-release, nigrostriatal damage, vesicles depletion), and nitric oxide-system disturbances ("L-NAME non-responsive, L-arginine responsive," and "L-NAME responsive, L-arginine responsive") (schizophrenia therapy); inflammation reduction, nerve recovery in addition to alleviated hemostasis and vessels function after compression (spinal cord injury therapy). Thus, these disturbances may be all resolved within the same agent's beneficial activity, i.e., the stable gastric pentadecapeptide BPC 157.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2021|Neural regeneration research
PubMed

This beneficial effect occurs equally when the gastrointestinal anastomoses are impaired with the application of NSAIDs, cysteamine, large bowel resection, as well as concomitant esophageal, gastric, and duodenal lesions and/or ulcerative colitis presentation, short bowel syndrome progression, liver and brain disturbances presentation. Particular aspects of the BPC 157 healing of the fistulas are especially emphasized.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2021|Current pharmaceutical design
PubMed

BPC 157 also has an effect on blood vessels, resulting in vessel recruitment that circumvents vessel occlusion and the development of additional shunting and rapid bypass loops to rapidly reestablish the integrity of blood flow (ischemic/reperfusion colitis, duodenal lesions, cecal perforation, and inferior vena caval occlusion). Lastly, BPC 157 counteracts tumor cachexia, muscle wasting, and increases in pro-inflammatory/procachectic cytokines, such as interleukin-6 and tumor necrosis factor-&#x3b1;, and significantly corrects deranged muscle proliferation and myogenesis through changes in the expression of FoxO3a, p-AKT, p-mTOR, and p-GSK-3&#x3b2; (mitigating cancer cachexia).

Limitations: No placebo control reported. Review article — no new primary data.

2021|Gut and liver
PubMed

Furthermore, gastrointestinal irritants such as physical or mental stress, NSAIDs administration, surfactants destroyer such as bile acids, alcohol can lead to leaky gut syndrome through increasing epithelial permeability. In this review article, we described the potential rescuing actions of BPC 157 against leaky gut syndrome after NSAIDs administration for the first time.

Limitations: No placebo control reported. Review article — no new primary data.

2021|Current pharmaceutical design
PubMed

BPC 157 counteracts electrocardiogram disturbances (increased P wave amplitude, S1Q3T3 QRS pattern and tachycardia). Rapidly presented vascular pathway (portal vein-superior mesenteric vein-inferior mesenteric vein-rectal veins-left ileal vein-inferior caval vein) as the adequate shunting immediately affected disturbed haemodynamics.

Limitations: Animal study only — human translation uncertain.

2020|World journal of hepatology
PubMed

Moreover, skeletal muscle injury models have suggested a beneficial effect not only for disturbances that occur as a result of direct trauma but also for systemic insults including hyperkalamia and hypermagnesia. Promisingly, there are few studies reporting any adverse reactions to the administration of BPC 157, although there is still a need to understand the precise healing mechanisms for this therapy to achieve clinical realisation.

Limitations: No placebo control reported. Review article — no new primary data.

2019|Cell and tissue research
PubMed

Contrary to this, BPC 157 - using same regimens like in gastrointestinal healing studies - improves tendon, ligament and bone healing, accurately implementing its own angiogenic effect in the healing. Thus, we claim that just BPC 157 represents in practice a pharmacological and pathophysiological role of various peptidergic growth factors.

Limitations: No placebo control reported. Review article — no new primary data.

2019|Current pharmaceutical design
PubMed

After obstruction (i.e., inferior caval vein), BPC 157 activates vessels "running" towards bypassing defect, collaterals functioning. Reestablished blood flow, and largely reversed injurious course may practically implement the cytoprotection concept.

Limitations: No placebo control reported. Review article — no new primary data.

2019|Current pharmaceutical design
PubMed

Also, BPC 157 particularly affects genes functions (i.e., Fos, c-Jun, Egr-1), all together suggestive for an indicative generalization. Thus, we could suggest gastric pentadecapeptide BPC 157 and BPC 157 induced-organoprotection as integrative mediator that integrates the adaptive bodily response to stress, and thereby practically applied in further therapy and in effective realization of Selye's stress response.

Limitations: No placebo control reported. Review article — no new primary data.

2018|Current pharmaceutical design
PubMed

BPC 157 may serve as a novel mediator of Robert's cytoprotection, involved in maintaining of GI mucosa integrity, with no toxic effect. BPC 157 was successful in the therapy of GI tract, periodontitis, liver and pancreas lesions, and in the healing of various tissues and wounds.

Limitations: No placebo control reported. Review article — no new primary data.

2017|Current neuropharmacology
PubMed

Bupivacaine (1mM) alone caused depolarization of the cells, while in combination with BPC 157 (1&#xb5;m), the bupivacaine-induced depolarization was inhibited. Together, these findings suggest that the stable gastric pentadecapeptide BPC 157 should be a potential antidote for bupivacaine cardiotoxicity.

Limitations: No placebo control reported.

2017|European journal of pharmacology
PubMed

However, how this advantage of modulating NO-system (i. e., particular effect on eNOS gene), may be practically translated into an enhanced clinical performance remains to be determined.

Limitations: No placebo control reported. Review article — no new primary data.

2015|Current pharmaceutical design
PubMed

Blood vessels are also strongly involved in tumor biology. In this aspect, we have neoangiogenesis resulting in pathological vascularization, vascular invasion resulting in release of metastatic cells and the phenomenon of homing resulting in formation of secondary tumors--metastases.

Limitations: No placebo control reported. Review article — no new primary data.

2015|Current pharmaceutical design
PubMed

Janus kinase 2, the downstream signal pathway of growth hormone receptor, was activated time-dependently by stimulating the BPC 157-treated tendon fibroblasts with growth hormone. In conclusion, the BPC 157-induced increase of growth hormone receptor in tendon fibroblasts may potentiate the proliferation-promoting effect of growth hormone and contribute to the healing of tendon.

Limitations: Animal study only — human translation uncertain.

2015|Molecules (Basel, Switzerland)
PubMed

Unlike NSAIDs, a very high safety (no reported toxicity (LD1 could be not achieved)) profile is reported for BPC 157. Also, unlike the different dosage levels of aspirin, as a NSAIDs prototype, which differ by a factor of about ten, all these beneficial and counteracting effects of BPC 157 were obtained using the equipotent dosage (&#x3bc;g, ng/kg) in parenteral or peroral regimens.

Limitations: No placebo control reported. Review article — no new primary data.

2013|Current pharmaceutical design
PubMed

Indicatively, unless counteracted in BPC 157 rats, excessive bleeding-acute thrombocytopenia (<20% of initial values in heparin-rats) approaches substantial fall in platelets count known in type II HIT. Also, BPC 157 markedly prolongs the survival time (heparin-rats, 25mg/kg, right foot amputation).

Limitations: Animal study only — human translation uncertain.

2012|Thrombosis research
PubMed

Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome and fistula healing indicate BPC 157's high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis.

Limitations: No placebo control reported. Review article — no new primary data.

2012|Current medicinal chemistry
PubMed

The protein expression and activation of FAK and paxillin were determined by Western blot analysis, and the phosphorylation levels of both FAK and paxillin were dose dependently increased by BPC 157 while the total amounts of protein was unaltered. In conclusion, BPC 157 promotes the ex vivo outgrowth of tendon fibroblasts from tendon explants, cell survival under stress, and the in vitro migration of tendon fibroblasts, which is likely mediated by the activation of the FAK-paxillin pathway.

Limitations: No placebo control reported.

2011|Journal of applied physiology (Bethesda, Md. : 1985)
PubMed

In short-bowel syndrome escalating throughout 4 weeks, the constant weight gain above preoperative values started immediately with peroral and parental BPC 157 therapy and the villus height, crypth depth and muscle thickness (inner (circular) muscular layer) additionally increased. Thus, BPC 157 may improve gastrointestinal tract therapy.

Limitations: No placebo control reported. Review article — no new primary data.

2011|Current pharmaceutical design
PubMed

Finally, the importance of the cytoprotection phenomena and cytoprotection activity for skin wound healing, and wound healing in general was challenged. Thereby, this review focused on BPC 157 role in cytoprotection and adaptative cytoprotection suggesting that it may be the essential endogenous mediator able to mediate both cytoprotective and adaptive cytoprotective response in stomach and the whole gastrointestinal tract with significant importance in wound healing as well.

Limitations: No placebo control reported. Review article — no new primary data.

2010|Current pharmaceutical design
PubMed

Given directly into the stomach, BPC 157 instantly recovers disturbed lower esophageal and pyloric sphincter pressure in rats after 12-20 months of untreated esophagitis. All these could be suggestive for its role as a natural protectant in gastric juice with particular function throughout stomach distension.

Limitations: No placebo control reported. Review article — no new primary data.

2007|Inflammopharmacology
PubMed

Thus, despite limitations, a generalization supporting a direct importance of a common cytoprotective approach, could be clearly provided. A useful, long-lasting cytoprotective activity (apparently more prominent in BPC 157 rats, than in reference agents, ranitidine, sucralfate, as well as cholestyramine) may be a likely suitable therapy in otherwise resistant reflux oesophagitis conditions.

Limitations: Animal study only — human translation uncertain.

2000|Journal of physiology, Paris
PubMed

The involvement of beta-receptor stimulation in BPC 157 gastroprotection appears to be related to the route of BPC 157 administration. The demonstration that a combined stimulation of adrenergic and dopaminergic systems by simultaneous prophylactic application of adrenaline (alpha- and beta-receptor stimulant) and bromocriptine (dopamine receptor agonist) may significantly reduce restraint stress lesions development provides insight for further research on the beneficial mechanism of BPC 157.

Limitations: Animal study only — human translation uncertain.

1997|Digestive diseases and sciences
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Limited human clinical data available
  • •Not approved by FDA for human use
  • •Long-term safety profile unknown
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get BPC-157, baseline labs & clinician oversight.

Full BPC-157 $/mg comparison →
50% OFF AUTO-APPLIED$2.45/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial Suppliers$6.00/mg

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy BPC-157: best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Ascension Peptides — $2.45/mg (10mg Lyophilized Vial, $24.50)
  2. 2. Elite Research USA — $4.00/mg (50mg vial, $200.00)
  3. 3. Ameano Peptides — $4.40/mg (10mg vial, $44.00)

Where is the cheapest place to buy BPC-157?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $2.45/mg (10mg Lyophilized Vial, $24.50 after the 50% new-customer partner-link discount). We compared 15 US suppliers with live, checked prices.

How much does BPC-157 cost per mg?

Verified US domestic prices currently range from $2.45/mg to $10.00/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is BPC-157 approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Popular Stacks

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.